Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Massachusetts

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

For decades, general health and science information has served as the foundation for public understanding of medical risks and therapeutic benefits. In the context of mass production, this legacy framework emphasized broad awareness of drug safety profiles and patient education, often focusing on common adverse effects and population-level outcomes. However, as pharmaceutical manufacturing scales to meet widespread demand, the occupational dimension of exposure becomes increasingly relevant. Workers involved in the production, handling, or packaging of biologic therapies may encounter substances that, while beneficial for patients, pose distinct hazards in the workplace. This shift from a patient-centered health perspective to an occupational exposure concern requires careful attention to the specific agents involved. In particular, exposure to Tysabri—a biologic used in the treatment of certain autoimmune conditions—has raised questions about the risk of progressive multifocal leukoencephalopathy (PML) among those who handle the drug during manufacturing or administration. The transition from general health literacy to focused occupational risk assessment is not merely a change in audience but a fundamental reorientation toward chronic, low-level exposure scenarios. This pivot sets the stage for examining legal considerations, such as the statute of limitations for Tysabri-related claims in Massachusetts, where the timing of exposure and onset of PML symptoms may determine the viability of a settlement.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Massachusetts who have developed PML after Tysabri exposure, understanding the medical evidence and legal time limits for filing a claim is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and physicians must weigh expected benefits against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinically, PML presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis relies on brain MRI and detection of JC virus DNA in cerebrospinal fluid. The prescribing information mandates that healthcare professionals "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Notably, PML has been reported even after discontinuation of Tysabri in patients without initial findings, so monitoring should continue for at least six months after stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JC virus, leading to lytic infection of oligodendrocytes and subsequent demyelination. The drug is available only through the restricted TOUCH Prescribing Program due to PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Statute of Limitations for Tysabri Claims in Massachusetts

Regarding settlement considerations, affected patients in Massachusetts must be aware of the statute of limitations for product liability claims. In Massachusetts, the general statute of limitations for personal injury actions is three years from the date the injury is discovered or reasonably should have been discovered. For Tysabri-related PML, the "discovery rule" may apply, meaning the clock starts when the patient knew or should have known that PML was caused by Tysabri. This could be at the time of diagnosis, or later if the link was not immediately apparent. Given the latency between exposure and harm, patients should document the timeline of Tysabri treatment, onset of symptoms, and PML diagnosis. The adequacy of warnings is a key issue: the boxed warning clearly states PML risk, but patients may argue that the risk was not adequately communicated or that they were not properly monitored. The prescribing information emphasizes that "risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), but whether this information was effectively conveyed to individual patients is a matter for legal review. The timeline between Tysabri exposure and documented PML harm is variable but often extends beyond two years of treatment. Patients who have received Tysabri for shorter durations may still be at risk, especially if they have anti-JCV antibodies or prior immunosuppressant use. For settlement purposes, the severity of PML—which "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)—is a critical factor in determining compensation. In summary, Massachusetts patients who developed PML after Tysabri treatment should seek legal counsel promptly to assess their claim within the three-year statute of limitations. Medical records documenting Tysabri use, PML diagnosis, and risk factors are essential. The evidence underscores that PML is a known, serious adverse effect of Tysabri, and the adequacy of warnings and monitoring will be central to any settlement or litigation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the general statute of limitations for personal injury actions is three years from the date the injury is discovered or reasonably should have been discovered. For Tysabri-related PML, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that PML was caused by Tysabri. It is crucial to seek legal counsel promptly to assess your claim within this timeframe.

What are the primary risk factors for developing PML from Tysabri?

The three primary risk factors identified are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.